Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Shares of Zai Lab rocketed to a 16-month high Thursday after the Chinese biotech posted "impressive" results for its lung cancer treatment.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

Zai Lab (ZLAB) presented data from the ongoing global Phase 1a/1b study of ZL-1310, a next-generation antibody-drug conjugate, or ADC, at the ...

Zai Lab (ZLAB) reported topline data from a Phase 3 study for KarXT in the treatment of schizophrenia, with plans to file for approval in China in early 2025. Read more here.

Zai Lab released Phase 1a data Thursday morning as it attempts to compete with a recently approved Amgen drug. The program, ...

SE (ARGNF) reports robust product sales growth and a solid cash position, while navigating increased expenses and competitive ...